Portal de Periódicos da CAPES

Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction

2015; Lippincott Williams & Wilkins; Volume: 26; Issue: 7 Linguagem: Inglês

10.1097/mca.0000000000000280

1473-5830

Özgür Akgül, Ömer Faruk Baycan, Ümit Bulut, Mustafa Umut Somuncu, Hamdi Püşüroğlu, Sinem Özyılmaz, Mehmet Gül, Ali Rıza Demir, Emre Yılmaz, Serkan Yazan, Uğur Köktürk, İlyas Çetin, Hüseyin Uyarel,

Biomarkers in Disease Mechanisms

Objectives The prognostic value of pentraxin 3 (PTX3) has been documented in patients with acute coronary syndrome. However, its long-term prognostic value in acute ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to evaluate the prognostic value of PTX3 in patients with STEMI undergoing a primary percutaneous coronary intervention (PCI). Methods We prospectively enrolled 499 consecutive STEMI patients undergoing primary PCI. The high-PTX3 group (n=141) was defined as having values in the third tertile (≥3.2 ng/ml) and the low-PTX3 group (n=358) included patients with values in the lower two tertiles (<3.2 ng/ml). Results The patients in the high-PTX3 group were older (mean age 54.3±11.8 vs. 58.5±13.1 years, P=0.002). Higher in-hospital cardiovascular mortality and 2-year all-cause mortality rates were observed in the high-PTX3 group (9.9 vs. 2.8%, respectively, P<0.001; 21 vs. 6.2%, respectively, P 3.2 ng/ml) was found to be an independent predictor of 2-year all-cause mortality (odds ratio: 2.3, 95% confidence interval: 1.20–4.90, P=0.025). Conclusion These results suggest that a high admission PTX3 level was associated with increased in-hospital cardiovascular mortality and 2-year all-cause mortality in patients with STEMI undergoing primary PCI.